{"entity":{"id":"nct04771871","kind":"trial","name":"MicroRNA Profiles in Triple Negative Breast Cancer","aka":["TARMAC"],"tldr":"A phase 2 trial of epirubicin, cyclophosphamide, paclitaxel / nab-paclitaxel and carboplatin in triple-negative breast cancer, run by University College Hospital, Ibadan, now recruiting.","summary":"MicroRNA Profiles in Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT04771871 by University College Hospital, Ibadan, with a registry enrolment figure of 42 participants, started 2021-11-29 and due to reach its primary completion in 2027-03. Interventions recorded: Epirubicin; Cyclophosphamide; Paclitaxel; Carboplatin. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Patients with histologically confirmed carcinoma of the female breast with triple negative status by immuno-histochemistry (IHC)\". Sites: Nigeria. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04771871","url":"https://clinicaltrials.gov/study/NCT04771871"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["epirubicin","cyclophosphamide","paclitaxel","carboplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04771871","phase":"2","setting":"Treatment Response and microRNA Profiles in Triple Negative Breast Cancer Patients Receiving Standard Chemotherapy","sponsor":"University College Hospital, Ibadan","enrolled":42,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04771871/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"epirubicin","kind":"drug","name":"Epirubicin","route":"/drugs/epirubicin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}